Jinghua Hua Wang

Address:

1981 W Smith Ct, La Habra, CA 90631

Phone:

(562)7130793

VIN:

JTJZK1BA4C2413462

Make:

LEXUS

Model:

RX 350

Year:

2012

US Patent:

60936924, Jul 25, 2000

Filed:

Sep 25, 1997

Appl. No.:

8/936898

Inventors:

Wei-Chiang Shen - San Marino CA
Jinghua Wang - South Pasadena CA

Assignee:

The University of Southern California - Los Angeles CA

International Classification:

A61K 3828

US Classification:

514 3

Abstract:

Fatty acid derivatives of disulfide-containing compounds (for example, disulfide-containing peptides or proteins) comprising fatty acid-conjugated products with a disulfide linkage are employed for delivery of the compounds to mammalian cells. This modification markedly increases the absorption of the compounds by mammalian cells relative to the rate of absorption of the unconjugated compounds, as well as prolonging blood and tissue retention of the compounds. Moreover, the disulfide linkage in the conjugate is quite labile in vivo and thus facilitates intracellular or extracellular release of the intact compounds from the fatty acid moieties.

US Patent:

20170231912, Aug 17, 2017

Filed:

Jan 30, 2017

Appl. No.:

15/419050

Inventors:

- Pomona CA, US
Guru V. BETAGERI - Chino Hills CA, US
Jinghua Jeffrey WANG - Arcadia CA, US

Assignee:

WESTERN UNIVERSITY OF HEALTH SCIENCES - Pomona CA

International Classification:

A61K 9/127
A61K 38/14

Abstract:

This invention is directed to a novel method of treating an individual suffering from a bacterial infection, such as bacterial infections of various tissues or organs of an individual. In general, the method of treatment involves administering to an individual a pharmaceutical formulation that comprises a liposome-encapsulated antimicrobial agent, wherein polyethylene glycol (PEG) molecules are covalently attached to the surface of the liposomes.

US Patent:

20160199345, Jul 14, 2016

Filed:

Sep 12, 2014

Appl. No.:

14/915965

Inventors:

- Pomona CA, US
Ying HUANG - Arcadia CA, US
Jinghua Jeffrey WANG - Arcadia CA, US
Ranadheer RAVULA - Atlanta GA, US
Zhi Jun WANG - Chino Hills CA, US

International Classification:

A61K 31/365
A61K 31/517
A61K 31/337
A61K 31/704

Abstract:

The invention provides compositions comprising wilforlide A for overcoming drug resistance in cancer therapy, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods and compositions for treating a cancer are disclosed. The method administers to a patient in need thereof a combination of wilforlide A and a chemotherapeutic drug. Wilforlide A and chemotherapeutic drug are administered in a combined amount effective to treat the can cer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug alone.

US Patent:

20150238553, Aug 27, 2015

Filed:

Aug 19, 2013

Appl. No.:

14/422216

Inventors:

- Pomona CA, US
Ying Huang - Arcadia CA, US
Jinghua Jeffrey Wang - Arcadia CA, US
Ranadheer Ravula - Atlanta GA, US
Zhi Jun Wang - Chino Hills CA, US

International Classification:

A61K 36/37
A61K 39/395
A61K 31/517
A61K 31/337
A61K 31/704

Abstract:

The invention provides extracts and compositions derived from for overcoming drug resist-ance in cancer therapy. This invention relates to organic solvent extracts of and their use in cancer treatment, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods of treating a cancer are disclosed. The method administers to a patient in need thereof a combination of (a) an organic solvent extract of and (b) a chemotherapeutic drug. The organic solvent extract of (a) and chemotherapeutic drug (b) are administered in a com-bined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug (b) alone. Also disclosed are chemotherapeutic compositions comprising a combination of (a) an organic solvent extract of and (b) a chemotherapeutic drug, wherein (a) and (b) are administered in a combined amount effective to treat the cancer; and a pharmaceutically acceptable carrier.